Search results
Results From The WOW.Com Content Network
While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.
Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
After being closed due to the ongoing debt crisis since 27 June 2015, the stock market crashed when the exchange was reopened on 3 August. The overall index lost over 16% of its value with bank stocks losing the maximum allowed 30% on the day's trading. The Athens Stock Exchange is a member of the Federation of Euro-Asian Stock Exchanges.
For premium support please call: 800-290-4726 more ways to reach us
Stock name Symbol Country of origin X Financial XYF: China: XAI Octagon Floating Rate & Alternative Income Term Trust XFLT: United States: XAI Octagon Floating Rate & Alternative Income Term Trust XFLT.PRA: United States Xenia Hotels & Resorts, Inc. XHR: United States Xinyuan Real Estate Co., Ltd. XIN: China XPeng Inc. XPEV: China Xperi Inc ...
For premium support please call: 800-290-4726 more ways to reach us
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.